Retrospective cohort study reveals esketamine's effectiveness and impacts on suicidal outcomes in treatment-resistant depression, suggesting real-world benefits.
In real-world clinical setting, ESK NS produces progressive improvements in depressive symptoms and functioning that often consolidating beyond the induction phase, especially during optimization phase.
No takes yet. Share an insight, caveat, or question.
García-Jiménez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: